Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
about
KASL clinical practice guidelines: management of chronic hepatitis BGenetic variation of hepatitis B virus and its significance for pathogenesisHepatitis B virus therapy: What's the future holding for us?Clinical Advances in Fibrosis Progression of Chronic Hepatitis B and CThe Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide AnalogsCurrent and future directions for treating hepatitis B virus infectionΜanagement of patients with hepatitis B and C before and after liver and kidney transplantationHepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawalTenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelinesAntiviral therapy for chronic hepatitis B in ChinaManagement of chronic hepatitis B infection: current treatment guidelines, challenges, and new developmentsThe importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysisDirect acting antivirals for the treatment of chronic viral hepatitisNucleoside/nucleotide analogues in the treatment of chronic hepatitis BTreatment strategies according to genotype for chronic hepatitis B in childrenAntiviral drug resistance: mechanisms and clinical implicationsEfficacy and safety of tenofovir in chronic hepatitis B: Australian real world experienceThe hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymesEfficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settingsChallenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection.Recent advances in micro/nanotechnologies for global control of hepatitis B infectionCurrent hepatitis B treatment guidelines and future research directions.Using multiple imputation to estimate cumulative distribution functions in longitudinal data analysis with data missing at random.Hepatitis B Virus Immunopathology, Model Systems, and Current TherapiesHepatitis B virus infection and alcohol consumptionEfficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study.Chronic hepatitis B: Advances in treatment.Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis BChronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study.TDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in China.Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage studyA Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B.Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B.Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelinesClinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B.Sequences in the terminal protein and reverse transcriptase domains of the hepatitis B virus polymerase contribute to RNA binding and encapsidationHepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activityPeginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials.
P2860
Q26752475-C6CDEC98-CA34-4161-B28A-81B647084719Q26772348-DEB6026A-E5EE-4FAF-A88F-AF42BE6CB72FQ26774198-8DA94221-F4AA-4A0D-923E-BF8CA082124AQ26781789-B80E6CE2-5A40-411B-900E-2CEE3759BC6EQ26781795-A32A41BC-2FFE-44BE-92EC-040217B2157EQ26851240-614DD809-512E-45A0-AFC7-DD8937447708Q26864647-8854E684-8F12-4C51-A595-ADF6D45F0C8BQ26995814-41121E7C-1E22-4AA7-9089-1459E4C06027Q26995852-CE72E638-6992-4337-9484-63815B20DD51Q27000080-A883A9DA-179A-43A5-BCA7-EAA299B96E08Q27006557-5CBB1C1A-035E-4668-A1C6-D5398885CEC0Q27008984-6D10C06C-055C-4484-8E31-CE484FA6BF57Q27016075-7B247ABC-E39F-4B62-9A1B-03412BCC30E4Q27022216-B9A37F97-D859-4DEE-9DFC-D67212DCA7C2Q27030828-FF40ED02-D34D-4727-A6D5-3F9DB416BCB9Q28066476-F0CEA05F-261D-452F-B50E-108E23A849BBQ28282376-C1C79E73-961D-4F63-B669-3DC265C4526FQ28468387-E8EF3BD8-0EE9-4760-85F1-8F963B02AE24Q28485228-1438A65D-37C2-45DD-A71A-7F9380049C1BQ28540372-A0F35FFB-9BB3-48C4-BFA2-C75434EA7BDEQ30244767-0DA115CF-98F2-434D-87F9-54C5201182B9Q30394611-A562CCF6-B11E-4AF1-B6E9-50952335A7E0Q30487002-B28C9788-970C-4B7F-B865-ECAAF81C8EC0Q30665870-F575AD5A-4F04-40BF-A359-DE277EFAB955Q33559657-F20E18BE-81C5-4EF2-AE13-1084F3B435FDQ33599503-C341B017-42E9-4123-A689-A1D60A4F1D02Q33608997-2A58C9F3-0C1F-4CA0-98AE-F8C2C8E750EFQ33660010-0D193DD4-1AE4-49DE-BB50-BB5FE704665DQ33676349-9EB44908-F128-49C4-81AC-2366697A7A45Q33718958-8DB103A0-CD78-4B37-B1A8-C60A59267D3DQ33746790-6E0A1BEE-A8B9-45ED-AFE9-37A3155DAD50Q33800724-A284EE59-8BF1-4446-8018-CAC1E7E97BC9Q33801743-F525687B-79DC-4123-9F14-F7B3F08F2B79Q33819098-D318DDC1-27FE-48C2-B35F-0F46B6F52D73Q33819124-61E6F142-0B96-4684-A5C4-98A72FA19EEFQ33855708-D563EC4A-AB48-42F0-A037-745BCF3C3412Q33872988-BDBB7FCD-51CC-49A5-A10E-DFD0D175CAF6Q33875691-A75F33A6-F3D7-4BFF-AE81-43A317EA256FQ33911464-15E1BE3F-429D-4693-9F8D-C4664D84968BQ33926126-AEF9CE1D-6BE8-4011-88EA-A08746A7FCDC
P2860
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
@en
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
@nl
type
label
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
@en
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
@nl
prefLabel
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
@en
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
@nl
P2093
P356
P1476
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
@en
P2093
Andrea Snow-Lampart
E Jenny Heathcote
Elsa Mondou
Franck Rousseau
Frank Weilert
George Germanidis
Iskren Kotzev
Jane Anderson
P304
P356
10.1056/NEJMOA0802878
P407
P577
2008-12-01T00:00:00Z